|
|
| | ALG1001 Basic information |
| Product Name: | ALG1001 | | Synonyms: | ALG1001;ALG1001
(Risuteganib;Risuteganib;L-Proline, glycyl-L-arginylglycyl-3-sulfo-L-alanyl-L-threonyl- | | CAS: | 1307293-62-4 | | MF: | C22H39N9O11S | | MW: | 637.66 | | EINECS: | | | Product Categories: | | | Mol File: | 1307293-62-4.mol |  |
| | ALG1001 Chemical Properties |
| density | 1.69±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | pka | 1.03±0.50(Predicted) |
| | ALG1001 Usage And Synthesis |
| Uses | Risuteganib is a synthetic RGD (arginyl-glycyl-aspartic acid)-class peptide. Risuteganib is an anti-integrin that downregulates oxidative stress and restores homeostasis, and targets three integrin receptors that are implicated in dry age-related macular degeneration (AMD) in order to restore homeostasis in the retina[1]. | | References | [1] Nebbioso M, et al. Therapeutic Approaches with Intravitreal Injections in Geographic Atrophy Secondary to Age-Related Macular Degeneration: Current Drugs and Potential Molecules. Int J Mol Sci. 2019 Apr 4;20(7). pii: E1693. DOI:10.3390/ijms20071693 |
| | ALG1001 Preparation Products And Raw materials |
|